Duopharma concludes supply deal for 6.4m doses of Sputnik V vaccine
KUALA LUMPUR: Duopharma Biotech Bhd has concluded the supply agreements with the Malaysian government and Russian Direct Investment Fund (RDIF) for the supply of 6.4 million doses of the Sputnik V vaccine.
In a statement, it said the supply of the vaccine is subject to the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.
Duopharma said Sputnik V was developed by Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology.
It has since been successfully registered in 68 countries across North and South America, the Middle East, Europe, Asia and Africa.